Medisafe 1 Technologies to develop new medical locking devices for intravenous administration

Medisafe 1 Technologies Corp. (OTCBB: MFTH), a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that that the company's board of directors has approved the research and development of two new medical locking device products.

In addition to the company's patented syringe locking device, the company will now seek to develop bar-coded locking devices for intravenous infusion bags, as well as blood transfusion bags.

It is estimated that the new technology will be ready for demonstration within three months' time.

The locking devices will physically prevent the intravenous administration of medications or blood, unless the prescribed dosages and/or blood type of the intended patient are first confirmed electronically.

"Human errors, both the improper labeling of bags as well as improper administration, are among the leading causes of blood transfusion related deaths," said, Jacob Elhadad, CEO of Medisafe 1 Technologies. "Applying the concepts behind our patented syringe bar-coding and locking device technology to transfusion and infusion bags can contribute to a reduction in the number of preventable deaths in hospitals.

"In addition, this technology can significantly reduce legal malpractice and hospital insurance fees," Elhadad added.

Source:

Medisafe 1 Technologies Corp.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
BMI's influence on disease pathogenesis uncovered in new research